Skip to Content

Developmental Research Program

**2014-2015 CALL FOR RESEARCH PROPOSALS**

The Uterine SPORE will solicit proposals for 2014-2015 Developmental Research (Pilot Project) funding in late April 2014. Please download and review the Pilot Project RFA (pdf) for specific details.

 

Directors

Thomas W. Burke, M.D. and Peter J. Davies, M.D., Ph.D.

The overall goal of the University of Texas MD Anderson Cancer Center Gynecologic SPORE for Uterine Cancers Developmental Research Program is to provide initial funding to support innovative translational studies and exploratory research in the area of gynecologic oncology and uterine cancer research. The support of translational research projects that can generate clinically testable hypotheses aimed at reducing the incidence and mortality of uterine cancers or leading to improved therapeutic outcomes or quality of life for uterine cancer patients will be emphasized.

Each year, pre-proposals in the form of project abstracts (1/2 -1 page) are solicited by the program, and applicants of responsive abstracts are invited to submit full pilot project proposals to the program. Proposals follow an abbreviated R01 research grant format and are up to 5 pages in length. The Developmental Research Program Directors, in conjunction with the SPORE Executive Committee, help investigators submitting proposals in formulating relevant translational research aims and plans, as many investigators may not have previous expertise in this area. This process is therefore a major educational activity with a goal to further stimulate translational research in gynecologic oncology and encourage the participation of both basic researchers and clinicians in translational research. With input from the Internal and External Advisory Committees, the SPORE Executive Committee makes the final selection of Pilot Projects for funding. Projects are funded for 1 year with the possibility of competitive renewal for an additional year. The program strives to fund at least 2 pilot projects each year. All projects are reviewed at the end of their first year with written progress reports and oral presentations at one of the SPORE meetings or retreats. Projects receiving an additional year of support will submit a final progress report at the end of their second year.

Funding Information

  • Solicitations for proposals come out late spring/early summer each year.
  • Funding is for $50,000 total costs.
  • Funding is for 1 year beginning September 1 and ending August 31 each year.
  • A progress report will be due at the end of the funding period.
  • Competitive renewal for 1 additional year is allowed.

Please call or e-mail Kristi Mercer (713-792-6884, knmercer@mdanderson.org) for further information or to get on the e-mail list for solicitations. Also, you may check the SPORE website for updates on solicitations.

Developmental Research Awards

2003-2004

  • Richard R. Behringer, Ph.D.
    UT MD Anderson Cancer Center
    Transgenic mice for endometrium-specific modifications
  • Jennifer K. Richer, Ph.D., and Meenakshi Singh, M.D.
    University of Colorado Health Sciences Center
    Alterations in co-activator levels in endometrial cancer

2004-2005

  • Mark T. Bedford, Ph.D.
    UT MD Anderson Cancer Center
    Arginine methyltransferases as novel therapeutic targets for endometrial carcinoma
  • Diego H. Castrillon, M.D., Ph.D.
    UT Southwestern
    Genetic mechanisms of endometrial carcinogenesis
  • Shi-Wen Jiang, M.D. and Sean Dowdy, M.D.
    Mayo Clinic
    Preclinical studies on epigenetic modification reagents for endometrial cancer treatment

2005-2006

  • Donghai Dai, M.D., Ph.D.
    University of New Mexico Health Science Center
    Synergistic anti-cancer effect of paclitaxel and amifostine in poor outcome endometrial cancer

2006-2007

  • Constance T. Albarracin, M.D., Ph.D.
    UT MD Anderson Cancer Center
    MicroRNA profiling to identify functional gene targets in endometrial carcinoma
  • Cheryl Walker, Ph.D.
    UT MD Anderson Cancer Center
    Using LKB1 Knockout Mouse Model to Develop New Models for Endometrial Carcinoma

2007-2008

  • Jae-Wook Jeong, Ph.D.
    Baylor College of Medicine
    The role of Mig-6 in the tumorigenesis of endometrial cancer
  • Bo Rueda, Ph.D.
    Harvard Medical School
    Delineating the unique gene expression features of the endometrial tumor initiating cell fraction
  • Anil K. Sood, M.D. and Robert Coleman, M.D.
    UT MD Anderson Cancer Center
    EphA2 targeting for anti-vascular therapy of endometrial carcinoma

2008-2009

  • Anil K. Sood, M.D. and Robert Coleman, M.D. (Renewal)
    UT MD Anderson Cancer Center
    EphA2 targeting for anti-vascular therapy of endometrial carcinoma

2010-2011

  • Daniel Carson, Ph.D.
    Rice University
    MUC1-Targeted Nanoparticle Therapy for Endometrial Cancers
  • Wei Zhang, Ph.D.
    UT MD Anderson Cancer Center
    Identification of Recurrent Genomic Aberrations as Potential Prognostic Markers and Therapeutic Targets in Endometrial Carcinoma

2011-2012

  • Daniel Carson, Ph.D. (Renewal)
    Rice University
    MUC1-Targeted Nanoparticle Therapy for Endometrial Cancers
  • Selvindiran Karuppaiyah, Ph.D.
    Ohio State University
    Targeting STAT3 for Molecular Therapy of Endometrial Cancer

2012-2013

  • Samuel Mok, Ph.D.
    UT MD Anderson Cancer Center
    The Role of Omentin in the Pathogenesis of Endometrial Cancer
  • Pedro Ramirez, M.D.
    UT MD Anderson Cancer Center
    High-Resolution Microendoscopy for Hysteroscopic Resection of Uterine Cancer

2013-2014

  • Samuel Mok, Ph.D.
    UT MD Anderson Cancer Center
    UHCL-1 as a Potential Therapeutic Target in Uterine Papillary Serous Carcinoma
  • Dharini van der Hoeven, Ph.D.
    University of Texas Health Science Center - Houston
    Characterization of Effect of Novel K-Ras Inhibitors on K-Ras-Transformed Tumor Growth in Mouse Model of Endometrial Cancer

© 2014 The University of Texas MD Anderson Cancer Center